Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 695

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Dr Sara A. Hurvitz presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the MONALEESA-7 trial.

This was a phase III randomised trial in which pre-menopausal women with advanced breast cancer received ribociclib on top of the standard of care endocrine therapy.

Read the news article here.

Watch the interview here.

Watch a comment from Dr Burstein here.

After 42 months of follow up, those receiving ribociclib had a survival rate of 70% compared with 46% for the placebo.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation